Beerse, Belgium (October 28, 2024) – Johnson & Johnson today announced that the European Commission (EC) has approved EDURANT® (rilpivirine) for the treatment of HIV-1 infection in adults and children weighing at least 25 kg without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class and with a viral load ≤ 100,000 HIV‑1 RNA copies/ml. To support expanded pediatric use, new 2.5 mg dispersible tablets have been developed for weight-adjusted dosing in children 2 to less than 18 years of age, weighing at least 14 kg and less than 25 kg.
Read the full press release here.
Source : Johnson & Johnson
Related HIV and Co-Infections News
-
Spotlight: South Africa’s ARV programme hardly grew in 2025, according to latest estimates
-
[Press release] ViiV Healthcare aims to close treatment gaps for children living with HIV with paediatric Dovato marketing applications to the EMA and FDA
-
Texas A&M University: Children with HIV are living longer but face a rising obesity risk
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.